Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature
by Buetler, V. A., Agbariah, N., Schild, D. P., Liechti, F. D., Wieland, A., Andina, N., Hammann, F., and Kremer Hovinga, J. A. (2022). Front. Med. 9:890661. doi: 10.3389/fmed.2022.890661
An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Bern.”
The original article has been updated.
Keywords: purpura, thrombotic thrombocytopenic, ADAMTS13, mRNA SARS-CoV-2 vaccine, COVID-19 vaccine
Citation: Frontiers Production Office (2023) Erratum: Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: Case report and mini-review of the literature. Front. Med. 10:1186494. doi: 10.3389/fmed.2023.1186494
Received: 14 March 2023; Accepted: 14 March 2023;
Published: 27 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org